## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.8% below STRENGTH zone (3.0-6.0%); PEG 1.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($701.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating**
- Source: marketscreener.com | 20251210T121414 | Somewhat-Bullish | Relevance: 99%
-  Wells Fargo has raised its price target for Regeneron Pharmaceuticals to $745 from $700, while maintaining an Equalweight rating on the stock. This adjustment comes amidst recent news regarding Regeneron's drug Lynozyfic showing impressive responses in treating newly diagnosed multiple myeloma. The article also lists other recent analyst adjustments and company news.

**2. How Investors May Respond To Regeneron (REGN) Lynozyfic Multiple Myeloma Data And Frontline Oncology Ambitions**
- Source: Simply Wall Street | 20251211T044726 | Somewhat-Bullish | Relevance: 98%
-  Regeneron Pharmaceuticals' Lynozyfic (linvoseltamab) monotherapy shows strong early data in newly diagnosed multiple myeloma patients, indicating its potential as a frontline treatment. While these results bolster Regeneron's oncology ambitions and pipeline, the company's investment narrative still largely depends on offsetting EYLEA competition with new blockbusters and diversified revenue streams. Investors must weigh the promising oncology developments against ongoing challenges in its established markets.

**3. State Street Corp Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251210T115453 | Bullish | Relevance: 98%
-  State Street Corp increased its stake in Regeneron Pharmaceuticals, Inc. by 0.9% in the second quarter, now holding 4,832,002 shares valued at approximately $2.54 billion. Analysts generally have a positive outlook on REGN, with an average rating of "Moderate Buy" and a price target of $777.36. Regeneron recently surpassed earnings and revenue estimates and pays a quarterly dividend.

**4. Intact Investment Management Inc. Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251211T122632 | Bullish | Relevance: 98%
-  Intact Investment Management Inc. significantly increased its stake in Regeneron Pharmaceuticals, Inc. (REGN) by 192.3% during the second quarter, bringing its total holdings to 2,280 shares valued at $1,197,000. Other institutional investors also modified their positions in REGN, which reported strong quarterly earnings and a recent dividend announcement. The company currently holds a "Moderate Buy" rating from analysts with an average target price of $779.41.

**5. ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline**
- Source: Medical Marketing and Media | 20251209T161534 | Bullish | Relevance: 98%
-  Regeneron presented new early data on two of its blood cancer drugs, linvoseltamab and odronextamab, at the American Society of Hematology (ASH) annual conference. Linvoseltamab showed efficacy as a monotherapy in newly diagnosed multiple myeloma, with a 70% very good or partial response rate. Odronextamab, in a trial combining it with CHOP chemotherapy for diffuse large B-cell lymphoma, achieved a 100% complete response rate among 13 patients.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($1.41M) |
| Sells | 12 ($16.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $17M sold (12 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +16%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +7.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +16%). Insider selling cluster ($16.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.2B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 19.5 |
| Current P/E | 17.3 |
| YoY Growth | -11.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.1% to 1.8% (+7.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.2pp (needs >3.0% for momentum thesis). MRS_5 at 4.1% confirms short-term momentum alignment. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-7.23), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.78% (CS: 58) | Neutral |
| RSI_14 | 60.6 | Neutral |
| MACD Histogram | -7.23 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.135x | Above |
| vs SMA200 | 1.247x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $746.80
- **Stop Loss:** $701.00 (6.1% risk)
- **Target:** $792.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 30
- **Position Value:** $22,404.00
- **Portfolio %:** 22.40%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*